Table of Content

1. What Is Cell Therapy?
1.1 Introduction
1.2 History & Evolution of Cell Therapy
1.3 Cell Therapy Classification


2. Mechanism of Therapeutic Action in Cell Therapy


3. Emergence of Personalized Cell Therapy
3.1 Overview of Personalized Cell Therapy
3.2 Personalized Cell Therapy Using Epigenetic Tools
3.3 Personalized Cell Therapy through Mesenchymal Stem Cells
3.4 Treatment of Parkinson’s Disease through IPSCs
3.5 Case Study: Personalized Cell Therapy for Pulpitis Using Autologous Dental Pulp
Stem Cells & Leukocyte Platelet Rich Fibrin


4. Cell Therapy Application by Therapeutic Areas
4.1 Cardiovascular Disease
4.2 Neurological Disorders
4.3 Inflammatory Diseases
4.4 Diabetes


5. Role of Cell Therapy In Cancer Therapeutics


6. Global Cell Therapy Clinical Trials 2021 -2028
6.1 By Phase
6.2 By Country/Region
6.3 By Company
6.4 By Indication
6.5 By Patient Segment
6.6 By Route Of Administration


7. Impact of COVID-19 On Cell Therapy Research Landscape


8. Global Cell Therapies Clinical Pipeline By Company, Indication & Phase
8.1 Unknown
8.2 Research
8.3 Preclinical
8.4 Clinical
8.5 Phase-0
8.6 Phase-I
8.7 Phase-I/II
8.8 Phase-II
8.9 Phase-II/III
8.10 Phase-III
8.11 Preregistration
8.12 Registered


9. Global Cell Therapy Market Outlook
9.1 Current Market Scenario
9.2 Cell Therapy Market by Cell Source


10. US - Cell Therapy Dosage & Cost Analysis
10.1 Allocord
10.2 Laviv
10.3 Maci
10.4 Clevecord
10.5 Hemacord
10.6 Ducord
10.7 Provenge
10.8 HPC, Cord Blood (Clinimmune Labs, University of Colorado Cord Blood Bank)
10.9 HPC, Cord Blood (LifeSouth Community Blood Centers, Inc)
10.10 HPC, Cord Blood (Bloodworks)
10.11 HPC, Cord Blood (MD Anderson Cord Blood Bank)
10.12 Gintuit
10.13 Kymriah*
10.14 Yescarta*
10.15 Carticel
10.16 Abecma (Idecabtagene Vicleucel)
10.17 Breyanzi (Lisocabtagene Maraleucel)


11. South Korea - Cell Therapy Dosage & Cost Analysis
11.1 Cartistem
11.2 Chondron
11.3 KeraHeal
11.4 Cellgram
11.5 Cure Skin Injection


12. Europe - Cell Therapy Dosage & Cost Analysis
12.1 Holoclar (Europe)
12.2 Yescarta (EU)
12.3 Kymriah (EU)
12.4 Alofisel (EU)
12.5 Strimvelis (EU)
12.6 Urocell (Germany/Switzerland/Belgium)
12.7 CellSpray (Belgium)


13. Japan - Cell Therapy Dosage & Cost Analysis
13.1 Temcell HS (Japan)
13.2 HeartSheet (Japan)
13.3 Stemirac


14. South Korea - Cell Therapy Dosage & Cost Analysis
14.1 Neuronata-R lenzumestrocel (South Korea)
14.2 Invossa-K (South Korea)
14.3 Adipocell / Cupistem/ Queencell (Korea)


15. Rest Of World - Cell Therapy Dosage & Cost Analysis
15.1 Chondrocytes-T-Ortho-ACI (Australia)
15.2 Prochymal (Canada/New Zealand)
15.3 Apceden (India)
15.4 BioCartII (Israel)
15.5 Nucel
15.6 CureXcell (Israel)


16. Global Cell Therapy Market Scenario
16.1 US
16.2 South Korea
16.3 Europe
16.4 Japan
16.5 China
16.6 Rest of the World


17. Cell Therapy Research Insights at University Level
17.1 Novel Autologous CAR-T Cell Therapy in Multiple Myeloma
17.2 Encouraging Cell Therapy Results with Cocoon Automated Platforms
17.3 CNCT19 Received Breakthrough Designation in China
17.4 Positive Results of MultiStem for ARDS in One-Bridge Study
17.5 MB-102 Initiated Phase-I/II Clinical Trial
17.6 G-NK Cells in Combination with Monoclonal Antibodies for Multiple Myeloma
17.7 Phase-III Trial Results of Omidubicel in Various Cancers
17.8 Novel Cell Therapy Combination shows Potential in NSCLC


18. Strategic Alliances for Promoting Cell Therapy Research
18.1 Kite Pharma & Appia Bio New Collaboration for Allogeneic Cell Therapy
18.2 New Strategic Collaboration for Novel Mitochondrial Cell Therapy Programs
18.3 Lilly & Sigilon Therapeutics to Develop Cell Therapies for Diabetes
18.4 Artiva Biotherapeutics Expand its Facilities in San Diego
18.5 Orion & Blood Service Launch Collaboration for Cancer Cell Therapy
18.6 Bayer & Atara Biotherapeutics Alliance for Cell Therapies in Solid Tumors
18.7 Tata Memorial Hospital & IIT Partnership for First CAR-T Cell Therapy in India
18.8 Mustang Bio Partnership with Mayo Clinic on Novel Cell Therapy
18.9 Cellares Partner with Poseida Therapeutics to Advance Cell Therapy
Manufacturing
18.10 Joint Venture by Orgenesis & Cure Therapeutics for Cell & Gene Therapies


19. Treg Cells – The Next Step To Advance Cell Therapy
19.1 Introduction to Treg Cell
19.2 Isolation & Expansion of Treg Cell
19.3 Mechanism of Action
19.4 Clinical Trials of Treg Cell Therapy
19.5 Treg Cell Therapy for the Treatment of Autoinflammatory & Autoimmune Diseases
19.6 Future Prospects of Treg Cell Therapy


20. Global Cell Therapy Market Future Prospects

21. Marketed Cell Therapies Clinical Insight by Company & Indication
21.1 Abecma
21.2 Yescarta
21.3 Breyanzi
21.4 NEURONATA-R
21.5 Provenge
21.6 RYONCIL / Prochymal
21.7 Kymriah
21.8 Chondrotransplant DISC
21.9 MACI
21.10 Carticel
21.11 STEMIRAC
21.12 HeartSheet
21.13 Strimvelis
21.14 Cartistem
21.15 Adipocell (Anterogen)
21.16 Alofisel
21.17 Zalmoxis
21.18 Cellgram
21.19 INVOSSA-K inj
21.20 APCEDEN for RCC
21.21 Laviv
21.22 BioCart
21.23 Gintuit
21.24 Holoclar
21.25 MyoCell
21.26 CellSpray
21.27 CureXcell
21.28 CHONDRON
21.29 NuCel
21.30 Dendritic Cell-Activated Cytokine-Induced killer Cells - Shanghai Jia Fu Medical
21.31 Urocell
21.32 Autologous chondrocyte implant – TETEC

22. Competitive Landscape
22.1 Athersys Inc.
22.2 Baxter Healthcare Corporation
22.3 Bone Therapeutics
22.4 Celgene Corporation
22.5 Cell Medica
22.6 Cellerant Therapeutics
22.7 FibrocellScinence
22.8 Genzyme Corporation
22.9 Green Cross Cell
22.10 Histogenics Corporation
22.11 Intrexon Corporation
22.12 Intercytex
22.13 ISTO Biologics
22.14 Macrocure
22.15 Mesoblast
22.16 Molmed
22.17 Nuo Therapeutics Inc
22.18 OmniCyte
22.19 Opexa Therapeutics
22.20 Organogenesis
22.21 Pharmicell
22.22 TCA Cellular Therapy
22.23 Stem Cell Inc.
22.24 Teva Pharmaceuticals
22.25 Tigenix
22.26 Vericel Corporation



List of Tables

Table 1-1: Difference between Allogeneic & Autologous Cell Therapy
Table 19-1: Functions of Effector T-Cell & Treg Cell